Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population
Top Cited Papers
Open Access
- 3 August 2010
- journal article
- research article
- Published by Wiley in Journal of Internal Medicine
- Vol. 268 (3), 296-308
- https://doi.org/10.1111/j.1365-2796.2010.02252.x
Abstract
Eugen‐Olsen J, Andersen O, Linneberg A, Ladelund S, Hansen TW, Langkilde A, Petersen J, Pielak T, Møller LN, Jeppesen J, Lyngbæk S, Fenger M, Olsen MH, Hildebrandt PR, Borch‐Johnsen K, Jørgensen T, Haugaard SB (Copenhagen University, Hvidovre Hospital, Hvidovre; Copenhagen University Hospital, Glostrup; Copenhagen University Hospital, Copenhagen; Copenhagen University Hospital, Glostrup; Copenhagen University, Hvidovre Hospital, Hvidovre; Steno Diabetes Center, Gentofte; University of Aarhus, Aarhus; University of Copenhagen, Copenhagen; Copenhagen University, Hvidovre Hospital, Hvidovre, Denmark). Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Intern Med 2010; 268: 296–308. Background. Low‐grade inflammation is thought to contribute to the development of cardiovascular disease (CVD), type‐2 diabetes mellitus (T2D), cancer and mortality. Biomarkers of inflammation may aid in risk prediction and enable early intervention and prevention of disease. Objective. The aim of this study was to investigate whether plasma levels of the inflammatory biomarker soluble urokinase plasminogen activator receptor (suPAR) are predictive of disease and mortality in the general population. Design. This was an observational prospective cohort study. Cohort participants were included from June 1993 to December 1994 and followed until the end of 2006. Setting. General adult Caucasian population. Participants. The MONICA10 study, a population‐based cohort recruited from Copenhagen, Denmark, included 2602 individuals aged 41, 51, 61 or 71 years. Measurements. Blood samples were analysed for suPAR levels using a commercially available enzyme‐linked immunosorbent assay. Risk of cancer (n = 308), CVD (n = 301), T2D (n = 59) and mortality (n = 411) was assessed with a multivariate proportional hazards model using Cox regression. Results. Elevated baseline suPAR level was associated with an increased risk of cancer, CVD, T2D and mortality during follow‐up. suPAR was more strongly associated with cancer, CVD and mortality in men than in women, and in younger compared with older individuals. suPAR remained significantly associated with the risk of negative outcome after adjustment for a number of relevant risk factors including C‐reactive protein levels. Limitation. Further validation in ethnic populations other than Caucasians is needed. Conclusion. The stable plasma protein suPAR may be a promising biomarker because of its independent association with incident cancer, CVD, T2D and mortality in the general population.Keywords
This publication has 41 references indexed in Scilit:
- C-Reactive Protein and Parental History Improve Global Cardiovascular Risk PredictionCirculation, 2008
- Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive ProteinNew England Journal of Medicine, 2008
- The interaction between urokinase receptor and vitronectin in cell adhesion and signallingEuropean Journal of Cell Biology, 2008
- Predicting mortality in patients with systemic inflammatory response syndrome: an evaluation of two prognostic models, two soluble receptors, and a macrophage migration inhibitory factorEuropean Journal of Clinical Microbiology & Infectious Diseases, 2008
- uPAR-induced cell adhesion and migration: vitronectin provides the keyThe Journal of cell biology, 2007
- Insulin Resistance, the Metabolic Syndrome, and Risk of Incident Cardiovascular Disease: A Population-Based StudyJournal of the American College of Cardiology, 2007
- Inflammation and insulin resistanceJCI Insight, 2006
- Structure of Human Urokinase Plasminogen Activator in Complex with Its ReceptorScience, 2006
- Inflammation, Atherosclerosis, and Coronary Artery DiseaseNew England Journal of Medicine, 2005
- Serum levels of soluble urokinase plasminogen activator receptor is associated with parasitemia in children with acute Plasmodium falciparum malaria infectionParasite Immunology, 2004